AI Summary & Key Takeaways
AI InsightRadiologists of varying experience demonstrated moderate agreement in detecting recurrence.
📌 3 Key Takeaways
Abstract
URPOSE Prostate multiparametric magnetic resonance imaging (mpMRl) has utility in detecting post—ra— diotherapy local recurrence. We conducted multireader study to evaluate the diagnostic per— formance of mpMRl for local recurrence after low dose rate (LDR) brachytherapy. METHODS total of 19 patients with biochemical recurrence after LDR brachytherapy underwent 3T en— dorectal coil mpMRl with T2—weighted imaging, dynamic contrast-enhanced imaging (DCE) and diffusion—weighted imaging (DWI) with pathologic confirmation. Prospective reads by an experi— enced prostate radiologist were compared with reads from radiologists of varying experience. Readers identified suspicious lesions and rated each MRI detection parameter. MRI—detected le— sions were considered true-positive with ipsilateral pathologic confirmation. Inferences for sen— sitivity, specificity, positive predictive value (PPV), kappa, and index of specific agreement were made with the use of bootstrap resampling. RESULTS Pathologically confirmed recurrence was found in 15 of 19 patients. True positive recurrences identified by mpMRl were frequently located in the transition zone (46.7%) and seminal vesicles (30%). On patient—based analysis, average sensitivity of mpMRl was 88% (standard error [SE], 3.5%). For highly suspicious lesions, specificity of mpMRl was 75% (SE, 16.5%). On lesion—based analysis, the average PPV was 62% (SE, 6.7%) for all lesions and 78.7% (SE, 10.3%) for highly sus— picious lesions. The average PPV for lesions invading the seminal vesicles was 88.8% (n=1 3). The average PPV was 66.6% (SE, 5.8%) for lesions identified with T2-weighted imaging, 64.9% (SE, 7.3%) for DCE, and 70% (SE, 7.3%) for DWI. CONCLUSION This series provides evidence that mpMRl after LDR brachytherapy is feasible with high pa— tient—based cancer detection rate. Radiologists of varying experience demonstrated moderate agreement in detecting recurrence.